Strongbridge Bio Ord (SBBP)

Company Profile

Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. The company is headquartered in Trevose, Pennsylvania and currently employs 72 full-time employees. The company went IPO on 2015-09-10. The firm is focused on the development and commercialization of therapies for a range of diseases. The firm's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The firm has a clinical-stage pipeline of therapies for endocrine diseases. The firm's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The firm is studying COR-003 for the treatment of endogenous Cushing's syndrome. The company is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).

Company Info

Strongbridge Bio Ord

900 Northbrook Dr Ste 200

Trevose PENNSYLVANIA 19053

P: 16102549200.0

CEO: John H. Johnson

Employees: 72

Website: http://www.strongbridgebio.com/